- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02111681
Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Jersey
-
Middletown, New Jersey, United States, 07748
- Memorial Sloan Kettering Monmouth
-
-
New York
-
Commack, New York, United States, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, United States, 10604
- Memorial Sloan Kettering West Harrison
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must have histologic proof of malignancy suitable for thoracic radiation therapy
- Patients planning to undergo radiation therapy for primary or recurrent malignancy of the lung or metastatic malignancy to the lung.
- Age ≥ 18 years old
- KPS ≥ 60%
- Ability to hold their breath for >20 seconds for 5 times
- Patients who are able to tolerate flexible bronchoscopy
- Patients with life expectancy of at least 12 months
- Patients able to have bronchoscopic placement of Calypso as confirmed on a recent (within the past 8 weeks) CT scan.
- Patients who are able to comply with the protocol follow-up schedule.
Exclusion Criteria:
- Patients unable to comply with instructions for DIBH
- Patients with implants in the chest region that contain metal or conductive materials (e.g., metal implants, rods, or plates) which Calypso Medical considers will interfere with the Calypso System's electromagnetic localization.
- Patients with active implanted devices, such as pacemakers, defibrillators, and drug infusion pumps since the effects of the Calypso System operation on these devices are unknown.
- Patients with clinically significant active infections.
- Patients with bronchiectasis in the region of the intended implantation sites.
- Patients with a history of hypersensitivity to nickel.
- Patients whose lung tumors are being monitored with MR imaging (MR imaging of the anchored transponders is safe but yields an image artifact around the anchored transponders).
- Posterior lesions that would be >19cm distance from Calypso detector plate. Patients may be treated in the prone position in order to meet the required minimum distance.
- Patients with any other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical study.
- Patients who are deemed unable to safely undergo or tolerate flexible bronchoscopy
- Patients who are unable to tolerate anesthesia or sedation
- Patients enrolled in any other clinical studies the investigator believes to be in conflict with this investigation.
- Female patients who are pregnant or nursing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Calypso-based Deep Inspiration Breath Hold (DIBH)
This trial will investigate the feasibility of implanted anchored Beacon ® electromagnetic lung transponders (Calypso ®) to guide and monitor deep-inspiration breathhold (DIBH) treatments in patients with inoperable thoracic malignancies. Bronchoscopic Calypso Beacon Implantation, Simulation - Free-breathing scan - 4D CT scan,- DIBH CT scan Radiation - Treatment setup, - Calypso signal recording, - RT treatment with DIBH with or without visual biofeedback Follow-up - 3 and 6 months after RT with diagnostic CT chest |
Bronchoscopic Calypso Beacon Implantation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of Calypso Transponders
Time Frame: 2 years
|
Feasibility is defined as completion of all treatments using the DIBH treatment plan and Calypso transponders.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reproducibility
Time Frame: 2 years
|
We will compare the visual vs no visual biofeedback treatments (done for each patient) by the number of treatment interruptions.
|
2 years
|
|
Measure the Residual Intrafraction Tumor Motion
Time Frame: 2 years
|
will be measured in all 3 dimensions and the euclidean distance will be calculated in milimeters/mm, which will then be correlated with the normal tissue dosimetry by regression analysis.
|
2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Daphna Gelblum, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13-174
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer (NSCLC)
-
Revolution Medicines, Inc.RecruitingNon-Small Cell Lung Cancer | NSCLC | NSCLC (Non-small Cell Lung Cancer) | NSCLC (Advanced Non-small Cell Lung Cancer) | NSCLC (Non-small Cell Lung Carcinoma)Japan, Netherlands, Hong Kong, United States, United Kingdom, Belgium, Australia, Spain, Germany, Switzerland, Italy, Taiwan, France, Singapore, Poland, South Korea, Puerto Rico, Ireland, New Zealand
-
H. Lee Moffitt Cancer Center and Research InstituteNestle Health ScienceWithdrawnNSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | NSCLC Stage IIIB | Non-small Cell Lung Cancer Stage IIIB | NSCLC, Stage IIIA | Non-small Cell Lung Cancer Stage ⅢAUnited States
-
Guangzhou University of Traditional Chinese MedicineGuang'anmen Hospital of China Academy of Chinese Medical Sciences; Beijing... and other collaboratorsNot yet recruitingNon Small Cell Lung Cancer NSCLCChina
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingNon Small Cell Lung Cancer NSCLCItaly
-
Mythic TherapeuticsTerminatedNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Spain, Taiwan, Australia, United Kingdom, France, South Korea
-
Massachusetts General HospitalSummit TherapeuticsNot yet recruitingLung Cancer Non Small Cell | Genomic Alterations | Lung Cancer (Non-Small Cell) | Lung Cancer (NSCLC) | Lung Cancer Non-Small Cell Cancer (NSCLC) | Lung Cancer - Non Small CellUnited States
-
Ono Pharmaceutical Co., Ltd.Bristol-Myers SquibbRecruiting
-
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.RecruitingSquamous Non-small Cell Lung Cancer(NSCLC)China
-
Multitude Therapeutics Inc.Not yet recruitingAdvanced Non-small Cell Lung Cancer (NSCLC)China
-
PfizerRecruitingCarcinoma | Lung Neoplasms | Non-Small Cell Lung Cancer | Lung Disease | Non-Small-Cell Lung | Carcinoma, Non-Small-Cell Lung (NSCLC) | Non-small Cell Lung Cancer, Squamous | Non-small Cell Lung Cancer, Non-squamous | Lung Cancer (NSCLC)United States, Puerto Rico
Clinical Trials on Calypso Beacon Implantation
-
Institut du Cancer de Montpellier - Val d'AurelleActive, not recruiting
-
Varian, a Siemens Healthineers CompanyCompletedLung CancerUnited States, Switzerland, Germany, South Africa
-
MoximedWithdrawnOsteoarthritis, Knee
-
ETH ZurichInsel Gruppe AG, University Hospital BernNot yet recruitingMortality | Respiratory Failure | Circulatory Failure | Organ Dysfunction | Organ Failure, MultipleSwitzerland
-
Andromeda SurgicalRecruitingBenign Prostatic HyperplasiaNew Zealand, Chile
-
MicroOptxTerminatedGlaucomaUnited States, Canada
-
Royal Brompton & Harefield NHS Foundation TrustImperial College London; Aalborg University; Mermaid Care A/SUnknownRespiratory Insufficiency | Mechanical Ventilation Complication | Critical Care | Respiration, Artificial | Intensive Care (ICU) MyopathyUnited Kingdom
-
Varian, a Siemens Healthineers CompanyCompleted
-
Duke UniversityCompletedPostoperative Infection | Complication of Surgical ProcedureUnited States
-
University of Wisconsin, MadisonCompletedAge-Related Macular Degeneration | Geographic AtrophyUnited States